<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75675">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02073344</url>
  </required_header>
  <id_info>
    <org_study_id>CIRS-SASinHD_005</org_study_id>
    <nct_id>NCT02073344</nct_id>
  </id_info>
  <brief_title>Effect of Beginning a Renal Replacement Therapy on Obstructive Sleep Apnea in End Stage Renal Disease Patients</brief_title>
  <acronym>SASinHD_005</acronym>
  <official_title>Prospective Interventional Study Investigating the Effect of Beginning a Renal Replacement Therapy on Obstructive Sleep Apnea and Its Correlation With Overhydration, in End Stage Renal Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of beginning a renal replacement
      therapy on fluid overload and its consequence on the severity of obstructive sleep apnea, in
      patients with end stage chronic kidney disease. It aims further to investigate the
      relationship between overhydration, nocturnal rostral fluid shift and the severity of sleep
      apnea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of obstructive sleep apnea increases with progressing renal insufficiency.
      Recent observations suggest a causative relationship between overnight fluid displacement
      from the legs to the neck soft tissues and the severity of obstructive sleep apnea. We
      suspect that this pathophysiologic mechanism could explain the increased prevalence of
      obstructive sleep apnea in patients with fluid overload, including chronic renal failure.

      The beginning of a renal replacement therapy modify the fluid balance of the end stage renal
      disease patients and could therefore impact on the severity of sleep apnea in this
      population.

      The purpose of this trial is to investigate the hypothesis that the transition from
      untreated end stage renal disease and a renal replacement therapy decreases the severity of
      sleep apnea, by a reduction of the fluid overload and of the nocturnal rostral fluid shift.

      The severity of obstructive sleep apnea is measured by two attended polysomnographies (PSG),
      a baseline PSG performed before and a follow-up PSG performed 6 month after beginning of a
      renal replacement therapy. Overhydration and leg fluid are evaluated by bioimpedance,
      performed at the beginning and at the end of each polysomnography. Patients who have not yet
      begun a renal replacement therapy 6 months after the baseline PSG will be re-assessed and
      will be analyzed as control group
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>obstructive sleep apnea severity</measure>
    <time_frame>six months (before and after beginning of a renal replacement therapy)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of the obstructive sleep apnea severity, measured by attended polysomnography, six months after beginning of a renal replacement therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>nocturnal leg fluid volume shift</measure>
    <time_frame>six months (before and after beginning of a renal replacement therapy)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction in nocturnal leg fluid volume shift between the legs and the neck, measured by bioimpedance and neck circumference six months after beginning of a renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship between overhydration, leg fluid volume shift, ankle and neck circumference and the severity of obstructive sleep apnea</measure>
    <time_frame>one night</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>periodic limb movement disorder (PLMD)</measure>
    <time_frame>six months (before and after beginning of a renal replacement therapy)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of central sleep apnea syndrome</measure>
    <time_frame>six months (before and after renal beginning of a renal replacement therapy)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Intevention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG 6 months after the beginning of a renal replacement therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No intervention A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already on renal replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal replacement therapy</intervention_name>
    <description>intermittent hemodialysis or peritoneal dialysis</description>
    <arm_group_label>Intevention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no renal replacement therapy</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate to severe obstructive sleep apnea, with an apnea-hypopnea index (AHI) ≥ 15/h

          -  age ≥ 18 years

          -  patient with end stage renal disease without renal replacement therapy.

        Exclusion Criteria:

          -  unstable congestive heart failure

          -  active psychiatric disease

          -  amputation of the lower limbs, proximal to the ankle
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphaël Heinzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation et Recherche sur le Sommeil (CIRS) - Centre Hospitalier Universitaire Vaudois (CHUV)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Ogna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation et Recherche sur le Sommeil (CIRS) - Centre Hospitalier Universitaire Vaudois (CHUV)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valentina Forni Ogna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation et Recherche sur le Sommeil (CIRS) - Centre Hospitalier Universitaire Vaudois (CHUV)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation et Recherche sur le Sommeil (CIRS) - Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raphaël Heinzer, MD</last_name>
      <phone>+41 21 314 67 48</phone>
      <email>raphael.heinzer@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Adam Ogna, MD</last_name>
      <phone>+41 21 314 67 48</phone>
      <email>adam.ogna@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Ogna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Forni Ogna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaël Heinzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Adam Ogna</investigator_full_name>
    <investigator_title>Centre d'Investigation et Recherche sur le Sommeil (CIRS)</investigator_title>
  </responsible_party>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>overhydration</keyword>
  <keyword>end stage renal disease</keyword>
  <keyword>renal transplantation</keyword>
  <keyword>polysomnography</keyword>
  <keyword>bioimpedance</keyword>
  <keyword>leg fluid shift</keyword>
  <keyword>neck circumference</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
